Bodyport

Bodyport is a digital therapeutics (DTx) company focused on empowering individuals to live free from complex chronic conditions. By leveraging unique health signals and simple, at-home experiences, the company delivers actionable insights. Bodyport is dedicated to advancing the standard of care for conditions like heart failure by integrating a sophisticated biomarker platform into easy-to-use devices, ultimately aiding patients and care teams in better predicting, understanding, and intervening in changes to heart health, thus reducing hospital visits. The platform noninvasively measures a broad spectrum of hemodynamic biomarkers to assess heart function and fluid status, providing comprehensive health insights directly to individuals at home. Founded in 2014 and headquartered in the United States, the company received a $11.20M Series A investment on 11 August 2020 from a group of investors including HCVC, Kapor Capital, Initialized Capital, Playground Global, BIVF, and El Cap Ventures. With its innovative approach and focus on digital therapeutics, Bodyport holds significant potential for contributing to the improvement of chronic condition management in the healthcare industry. Learn more about the company at bodyport.com.